BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Clinical Trials
1.7k
Trial Phases
6 Phases
Drug Approvals
11
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (1345 trials with phase data)• Click on a phase to view related trials
Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2025-11-03
- Last Posted Date
- 2025-11-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT07223671
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
- Conditions
- Advanced Solid MalignanciesNon-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- First Posted Date
- 2025-10-31
- Last Posted Date
- 2025-10-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 252
- Registration Number
- NCT07223047
- Locations
- 🇺🇸
Local Institution - 0001, San Antonio, Texas, United States
🇺🇸Local Institution - 0007, Salt Lake City, Utah, United States
🇺🇸Local Institution - 0011, Fairfax, Virginia, United States
A Study to Evaluate the Effect of KarXT on Urological Safety
- Conditions
- Schizophrenia
- Interventions
- Drug: Xanomeline/trospium chloride
- First Posted Date
- 2025-10-28
- Last Posted Date
- 2025-10-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT07221877
- Locations
- 🇺🇸
Local Institution - 0017, Little Rock, Arkansas, United States
🇺🇸Local Institution - 0007, Bellflower, California, United States
🇺🇸Local Institution - 0009, Culver City, California, United States
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
- Conditions
- Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2025-10-27
- Last Posted Date
- 2025-10-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 690
- Registration Number
- NCT07221149
- Locations
- 🇺🇸
Local Institution - 0284, Phoenix, Arizona, United States
🇺🇸Local Institution - 0240, Los Angeles, California, United States
🇺🇸Local Institution - 0277, Orange, California, United States
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- Conditions
- Untreated, Unresectable, or Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2025-10-27
- Last Posted Date
- 2025-10-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 990
- Registration Number
- NCT07221357
- Locations
- 🇺🇸
Local Institution - 0263, Los Angeles, California, United States
🇺🇸Local Institution - 0345, Orange, California, United States
🇺🇸Local Institution - 0317, Sacramento, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 301
- Next
News
DBV Technologies Appoints Kevin Trapp as Chief Commercial Officer Ahead of Viaskin Peanut Patch BLA Submission
DBV Technologies has appointed Kevin Trapp as Chief Commercial Officer to lead global commercial strategy for the Viaskin Peanut patch ahead of anticipated regulatory submissions.
HRSA Approves Eight Drug Companies for 340B Rebate Model Pilot Program Starting January 2025
The Health Resources and Services Administration has approved eight pharmaceutical companies to participate in the 340B Rebate Model Pilot Program, which will begin on January 1, 2025.
FDA Proposes Streamlined Approval Pathway to Accelerate Biosimilar Drug Development
The U.S. FDA released draft guidance proposing to reduce human clinical study requirements for certain biosimilar drugs and treat them more like generic medications to accelerate market availability.
CAR-T Therapies from Cabaletta Bio and Bristol Myers Squibb Achieve Complete Remissions in Severe Inflammatory Muscle Disease
Experimental CAR-T therapies from Cabaletta Bio and Bristol Myers Squibb have induced complete remissions in patients with severe inflammatory muscle disease, according to dual clinical trial results presented this week.
Evotec Receives $25M Milestone Payment from Bristol Myers Squibb for Neuroscience Partnership Progress
Evotec received a $25 million payment from Bristol Myers Squibb for achieving scientific progress in their strategic neuroscience partnership focused on neurodegenerative diseases.
Bristol Myers Squibb Reports Promising CAR-T Cell Therapy Results for Three Autoimmune Diseases
Bristol Myers Squibb presented Phase 1 data from 71 patients showing its CD19 NEX-T CAR-T therapy achieved immune reset across three severe autoimmune diseases with 94% of patients remaining off immunosuppressive therapy.
Biokin Receives Record $250 Million ADC Milestone Payment from Bristol Myers Squibb
Biokin secured a $250 million milestone payment from Bristol Myers Squibb in October 2025, marking the largest antibody-drug conjugate milestone payment among Chinese innovative drug out-licensing deals.
Flagship Pioneering Launches Expedition Medicines with $50M Investment in AI-Driven Covalent Drug Discovery
Flagship Pioneering has launched Expedition Medicines with a $50 million investment, focusing on AI-driven drug discovery for cancer and immune diseases using covalent chemistry principles.
Takeda Expands AI Drug Discovery Partnership with Nabla Bio in $1B+ Deal
Takeda Pharmaceutical has signed a second multi-year AI partnership with Nabla Bio, potentially worth over $1 billion including milestone payments, to accelerate early-stage drug discovery using artificial intelligence.
iMDx Appoints Marketing VP to Spearhead Commercial Launch of Transplant Rejection Diagnostic
Insight Molecular Diagnostics (iMDx) has appointed Steven Tahmooressi as Vice President of Marketing to lead the commercial launch of its GraftAssureDx transplant rejection diagnostic kit.